Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:NantCell,_Inc.
|
| gptkbp:advertising |
focus on oncology market
|
| gptkbp:budget |
available to shareholders
|
| gptkbp:businessModel |
cell therapy
|
| gptkbp:CEO |
gptkb:Patrick_Soon-Shiong
|
| gptkbp:clinicalTrials |
ongoing studies
various hospitals and clinics various cancer treatments biopharmaceutical company published in scientific journals Phase 1 and Phase 2 |
| gptkbp:collaborations |
gptkb:NantWorks
academic institutions with leading research institutions |
| gptkbp:community_engagement |
involvement in cancer awareness programs
|
| gptkbp:community_service |
collaboration with patient groups
various efficacy measures |
| gptkbp:financialPerformance |
reported quarterly
fluctuates with market conditions |
| gptkbp:financials |
available on website
|
| gptkbp:focus |
immunotherapy
|
| gptkbp:founded |
2015
|
| gptkbp:founder |
gptkb:Patrick_Soon-Shiong
|
| gptkbp:funding |
secured from various sources
|
| gptkbp:future_plans |
expand product pipeline
promising based on research progress |
| gptkbp:headquarters |
gptkb:Culver_City,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
NantKwest
|
| gptkbp:innovation |
in cancer treatment technologies
|
| gptkbp:investmentFocus |
various venture capital firms
publicly available information significant funding rounds |
| gptkbp:market |
approximately $1 billion
|
| gptkbp:mission |
transform cancer treatment
|
| gptkbp:partnerships |
various pharmaceutical companies
regularly updated biotech and pharma companies |
| gptkbp:platforms |
NK cell engineering
|
| gptkbp:products |
focused on immuno-oncology
|
| gptkbp:publications |
numerous peer-reviewed articles
|
| gptkbp:reach |
international collaborations
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
for new therapies |
| gptkbp:research |
gptkb:Dr._David_L._H._Hwang
|
| gptkbp:research_areas |
oncology
various NK cell therapies |
| gptkbp:research_focus |
cancer and infectious diseases
|
| gptkbp:social_responsibility |
commitment to ethical practices
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
NK
|
| gptkbp:supplyChain |
NantKwest's_NK_cell_therapy
|
| gptkbp:supportRole |
composed of industry experts
|
| gptkbp:team |
experienced professionals in biotech
|
| gptkbp:technology |
natural killer cell therapy
in cell therapy |
| gptkbp:tributaryOf |
multiple oncology products
|
| gptkbp:vision |
personalized medicine
|